Healthcare and Life Sciences Brace for Policy Impact

60% of industry leaders expect tariffs and pricing policies to affect business operations

  60% of industry leaders expect tariffs and pricing policies to affect business operations

A new Deloitte survey reveals that the healthcare and life sciences sectors are preparing for significant disruption from evolving trade and pricing policies. The study, conducted in late June 2025 with 120 global executives, found that three in five industry leaders anticipate at least "some impact" from current and anticipated regulatory changes.

 

Strategic Planning vs. Operational Readiness

While companies are actively engaging in scenario planning, a gap appears to exist between strategic preparation and operational execution:

  • 73% of US-based firms have implemented scenario-planning strategies
  • 64% have taken steps to secure supply chains against global disruptions
  • Only 10% have altered organizational structures

 

The survey suggests most organizations remain in planning mode rather than implementing transformative operational changes.

 

Key Industry Responses

Life sciences companies are adapting their business models in several ways:

 

R&D Investment: Despite policy uncertainty, 60% of companies are maintaining current research and development funding levels while adjusting strategies around clinical trial locations and supply sourcing.

 

Manufacturing Shifts: 17% of respondents plan to relocate manufacturing to the US, with 62% expecting new facilities to be operational within five years.

 

Service Evaluation: Half of surveyed companies are reassessing how policy changes might affect services including digital health offerings and patient support programs.

 

The "Quantum Corporation" Approach

Deloitte researchers advocate for what they term "quantum corporation" strategies—organizations that operate in parallel states of readiness and build infrastructure for multiple potential outcomes simultaneously. This hyper-adaptive approach emphasizes continuous learning and real-time operational adjustments over traditional contingency planning.

 

The survey was conducted prior to the enactment of the One Big Beautiful Bill Act (OBBBA), signed into law on July 4, 2025, suggesting additional impacts may emerge as companies respond to the new legislation.

 

The full Deloitte report emphasizes that organizations combining strategic foresight with operational agility will be best positioned to navigate the evolving regulatory landscape.


Source: https://www.deloitte.com/us/en/Industries/life-sciences-health-care/blogs/health-care/sixty-percent-life-sciences-health-care-firms-expect-impact-from-tariffs-policy.html

 

Georgia Life Sciences Joins National Coalition Urging Congressional Action on Key Innovation Policies

December 10, 2025
Georgia Life Sciences has joined 43 state and regional life sciences organizations in signing a national Council of State Bioscience Associations (CSBA) letter calling on Congress to take immediate action on three bipartisan policy priorities that are essential to sustaining U.S. leadership in biomedical innovation and supporting patients nationwide. With Congress back in session and several critical programs at risk of expiring, the letter urges congressional leaders to advance the following provisions without delay: 1. Reauthorize the Rare Pediatric Disease Priority Review Voucher (PPRV) Program The PPRV program has been instrumental in incentivizing the development of therapies for children with rare and life-threatening conditions. Its lapse threatens to slow or halt research that families across the country are counting on. 2. Extend the SBIR/STTR Programs The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide crucial early-stage capital for emerging biotech and medtech companies—many of them in Georgia. Without reauthorization, hundreds of innovative small businesses face uncertainty, jeopardizing new therapies, diagnostics, and technologies in the pipeline, 3. Advance PBM Transparency Reforms Greater transparency and accountability within pharmacy benefit manager (PBM) practices are needed to ensure that savings reach patients and employers. Reforming PBM operations is essential to strengthening access and affordability across the healthcare system. A Unified Message from the Life Sciences Community The sign-on letter reflects broad, bipartisan alignment across the national life sciences ecosystem: researchers, entrepreneurs, investors, patient advocates, and state associations all share a common message— these programs underpin America’s global competitiveness and are vital to patients who rely on continued scientific progress. Georgia Life Sciences has shared the letter with members of Georgia’s congressional delegation and will continue engaging with policymakers to emphasize the importance of swift action.

GLS Joins Georgia Partners in Calling for Federal PBM Reform

December 7, 2025
Georgia Life Sciences is proud to stand with patient advocates, providers, and employers across the state in urging Congress to take meaningful action on pharmacy benefit manager (PBM) reform. We recently signed on to a joint letter to Georgia’s Congressional Delegation stressing the urgent need for transparency, fair practices, and policies that ensure savings flow directly to patients.

GLS’ President and CEO, Maria Thacker Goethe in December's issue of Georgia Trend

December 4, 2025
Georgia Life Sciences’ CEO, Maria Thacker Goethe shares her perspective on the value of Georgia’s research universities in this month’s issue of Georgia Trend. “Georgia research institutions have felt a very significant impact from the federal rollbacks, specifically in NIH and NSF funding. Thacker Goethe’s message about the impact of research cuts is simple: Disruption shatters the foundational trust researchers have in grant continuity….” To read the full article, click here .
MORE POSTS